Differential effect of endogenous glucagon-like peptide-1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery

Diabetes Obes Metab. 2024 Jun;26(6):2476-2486. doi: 10.1111/dom.15570. Epub 2024 Apr 1.

Abstract

Aim: To determine the effect of endogenous glucagon-like peptide 1 (GLP-1) on prandial counterregulatory response to hypoglycaemia after gastric bypass (GB).

Materials and methods: Glucose fluxes, and islet-cell and gut hormone responses before and after mixed-meal ingestion, were compared during a hyperinsulinaemic-hypoglycaemic (~3.2 mmol/L) clamp with and without a GLP-1 receptor (GLP-1R) antagonist exendin-(9-39) infusion in non-diabetic patients who had previously undergone GB compared to matched participants who had previously undergone sleeve gastrectomy (SG) and non-surgical controls.

Results: Exendin-(9-39) infusion raised prandial endogenous glucose production (EGP) response to insulin-induced hypoglycaemia in the GB group but had no consistent effect on EGP response among the SG group or non-surgical controls (p < 0.05 for interaction). The rates of systemic appearance of ingested glucose or prandial glucose utilization did not differ among the three groups or between studies with and without exendin-(9-39) infusion. Blockade of GLP-1R had no effect on insulin secretion or insulin action but enhanced prandial glucagon in all three groups.

Conclusions: These results indicate that impaired post-meal glucose counterregulatory response to hypoglycaemia after GB is partly mediated by endogenous GLP-1, highlighting a novel pathogenic mechanism of GLP-1 in developing hypoglycaemia in this population.

Keywords: counterregulatory response; gastric bypass; glucagon‐like peptide 1; hypoglycaemia.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Bariatric Surgery / adverse effects
  • Blood Glucose* / metabolism
  • Female
  • Gastrectomy / adverse effects
  • Gastric Bypass* / adverse effects
  • Glucagon-Like Peptide 1* / metabolism
  • Glucagon-Like Peptide-1 Receptor / agonists
  • Glucagon-Like Peptide-1 Receptor / metabolism
  • Glucose Clamp Technique
  • Humans
  • Hypoglycemia* / metabolism
  • Hypoglycemia* / prevention & control
  • Insulin / metabolism
  • Male
  • Middle Aged
  • Obesity, Morbid / metabolism
  • Obesity, Morbid / surgery
  • Peptide Fragments / administration & dosage
  • Postprandial Period

Substances

  • Glucagon-Like Peptide 1
  • Blood Glucose
  • exendin (9-39)
  • Glucagon-Like Peptide-1 Receptor
  • Peptide Fragments
  • Insulin